@article{Koseoglu_Tuncel_Balci_Kaya_Aslan_Guzel_Meric Yilmaz_Atan_2018, title={Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer}, volume={49}, url={https://colombiamedica.univalle.edu.co/index.php/comedica/article/view/3901}, DOI={10.25100/cm.v49i2.3011}, abstractNote={<p>Objectives: To investigate serum and urine levels of Alphamethylacyl-CoA-racemase (AMACR) and Netrin 1 in patients with and without prostate cancer and to determine whether these markers could be used as alternatives in diagnosis of prostate cancer instead of serum prostate specific antigen (PSA) levels.</p> <p>Methods: One hundred and seventy five patients between 45-75 years to whom transrectal ultrasound guided biopsies were performed for abnormal serum PSA levels or digital rectal examinations were included. The levels of AMACR and Netrin 1 levels of blood and urine samples of 5 mL those were taken prior to biopsies were measured.</p> <p>Results: The mean age of the patients was 62.7 ±6.4 years. Prostate cancer was detected in 40 patients (22.8%) while 135 of them (77.2%) were diagnosed as benign prostate hyperplasia (BPH). In BPH group, serum and urine levels of AMACR and Netrin 1 were 13.4 ±16.9 ng/mL; 7.1 ±3.4 ng/mL; 164.1 ±46 pg/mL and 19.5±5 pg/mL respectively. The levels of serum and urine levels of AMACR and Netrin 1 were 10.2 ±9.8 ng/mL; 6.8 ±2.5 ng/mL; 159.1 ±44.1 pg/mL and 20.1 ±5.3 pg/mL respectively in prostate cancer group. There was no statistically significant difference or correlation between these two groups serum and urine AMACR and Netrin 1 results</p> <p>Conclusions: Serum and urine levels of AMACR and Netrin 1 were not found to be alternatives for serum PSA levels in the diagnosis of prostate cancer in this study.</p>}, number={2}, journal={Colombia Medica}, author={Koseoglu, Ersin and Tuncel, Altug and Balci, Melih and Kaya, Oguzhan and Aslan, Yılmaz and Guzel, Ozer and Meric Yilmaz, Fatma and Atan, Ali}, year={2018}, month={Jun.}, pages={164–168} }